
    
      This is a single-arm open label interventional safety trial with RP patients, who receive
      weekly TES for 6 months on 1 eye followed by observation for another 6 months without
      stimulation. The primary outcome measure is safety, indicated by the frequency and severity
      of adverse events.
    
  